Cochrane · systematic review · CD002201
Omega‐3 fatty acid supplementation for cystic fibrosis
Watson, H, Stackhouse, C · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 6 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: omega‐3 fatty acid supplementation compared with placebo for cystic fibrosis
Population: children and adults with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of pulmonary exacerbations (median number of exacerbations during the study) Summary of findings: omega‐3 fatty acid supplementation vs placebo | no estimate extracted | 1 study · 13 participants | Very low Downgraded: risk of bias |
Adverse events: diarrhoea Summary of findings: omega‐3 fatty acid supplementation vs placebo | OR 0.6 [0.05, 6.79] | 1 study · 12 participants | Very low Downgraded: risk of bias, imprecision |
FEV1 % predicted Summary of findings: omega‐3 fatty acid supplementation vs placebo | MD 2 [19.11, 23.11] | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
FVC % predicted Summary of findings: omega‐3 fatty acid supplementation vs placebo | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision |
Growth and nutrition: BMI SD score Summary of findings: omega‐3 fatty acid supplementation vs placebo | MD 0 | 1 study · 29 participants | Very low Downgraded: risk of bias, imprecision |
Biochemical markers of essential fatty acid status: EPA and DHA % content of neutrophil membrane Summary of findings: omega‐3 fatty acid supplementation vs placebo | no estimate extracted | 1 study · 29 participants | Very low Downgraded: risk of bias, imprecision |